Skip to main content
Erschienen in: Supportive Care in Cancer 4/2009

01.04.2009 | Original Article

Evaluation of a mobile phone-based, advanced symptom management system (ASyMS©) in the management of chemotherapy-related toxicity

verfasst von: N. Kearney, L. McCann, J. Norrie, L. Taylor, P. Gray, M. McGee-Lennon, M. Sage, M. Miller, R. Maguire

Erschienen in: Supportive Care in Cancer | Ausgabe 4/2009

Einloggen, um Zugang zu erhalten

Abstract

Objectives

To evaluate the impact of a mobile phone-based, remote monitoring, advanced symptom management system (ASyMS©) on the incidence, severity and distress of six chemotherapy-related symptoms (nausea, vomiting, fatigue, mucositis, hand–foot syndrome and diarrhoea) in patients with lung, breast or colorectal cancer.

Design

A two group (intervention and control) by five time points (baseline, pre-cycle 2, pre-cycle 3, pre-cycle 4 and pre-cycle 5) randomised controlled trial.

Setting

Seven clinical sites in the UK; five specialist cancer centres and two local district hospitals.

Participants

One hundred and twelve people with breast, lung or colorectal cancer receiving outpatient chemotherapy.

Interventions

A mobile phone-based, remote monitoring, advanced symptom management system (ASyMS©).

Main outcome measures

Chemotherapy-related morbidity of six common chemotherapy-related symptoms (nausea, vomiting, fatigue, mucositis, hand–foot syndrome and diarrhoea).

Results

There were significantly higher reports of fatigue in the control group compared to the intervention group (odds ratio = 2.29, 95%CI = 1.04 to 5.05, P = 0.040) and reports of hand–foot syndrome were on average lower in the control group (odds ratio control/intervention = 0.39, 95%CI = 0.17 to 0.92, P = 0.031).

Conclusion

The study demonstrates that ASyMS© can support the management of symptoms in patients with lung, breast and colorectal cancer receiving chemotherapy.
Literatur
2.
Zurück zum Zitat Department of Health (2007) Cancer reform strategy—executive summary. Department of Health (2007) Cancer reform strategy—executive summary.
4.
Zurück zum Zitat Park VJ, Trovato JA (2004) Frequency of nausea and vomiting after chemotherapy. Am J Health Syst Pharm 61:722–723PubMed Park VJ, Trovato JA (2004) Frequency of nausea and vomiting after chemotherapy. Am J Health Syst Pharm 61:722–723PubMed
5.
Zurück zum Zitat Dranitsaris G, Maroun J, Shah A (2005) Estimating the cost of illness in colorectal cancer patients who were hospitalized for severe chemotherapy-induced diarrhoea. Can J Gastroenterol 19(2):83–87PubMed Dranitsaris G, Maroun J, Shah A (2005) Estimating the cost of illness in colorectal cancer patients who were hospitalized for severe chemotherapy-induced diarrhoea. Can J Gastroenterol 19(2):83–87PubMed
6.
Zurück zum Zitat Polednak AP (2004) Surveillance for hospitalizations with infection-related diagnoses after chemotherapy among breast cancer patients diagnosed before age 65. Chemotherapy 50(4):157–161 doi:10.1159/000080688 PubMedCrossRef Polednak AP (2004) Surveillance for hospitalizations with infection-related diagnoses after chemotherapy among breast cancer patients diagnosed before age 65. Chemotherapy 50(4):157–161 doi:10.​1159/​000080688 PubMedCrossRef
8.
Zurück zum Zitat Chen-Hardee S, Chrischilles EA, Voelker MD, Brooks JM, Scott S, Link BK et al (2006) Population-based assessment of hospitalizations for neutropenia from chemotherapy in older adults with non-Hodgkin's lymphoma (United States). Cancer Causes Control 17(5):647–654 doi:10.1007/s10552-005-0502-4 PubMedCrossRef Chen-Hardee S, Chrischilles EA, Voelker MD, Brooks JM, Scott S, Link BK et al (2006) Population-based assessment of hospitalizations for neutropenia from chemotherapy in older adults with non-Hodgkin's lymphoma (United States). Cancer Causes Control 17(5):647–654 doi:10.​1007/​s10552-005-0502-4 PubMedCrossRef
9.
Zurück zum Zitat Kuderer NM, Dale DC, Crawford J, Cosler LE, Lyman GH (2006) Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients. Cancer 106(10):2258–2266 doi:10.1002/cncr.21847 PubMedCrossRef Kuderer NM, Dale DC, Crawford J, Cosler LE, Lyman GH (2006) Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients. Cancer 106(10):2258–2266 doi:10.​1002/​cncr.​21847 PubMedCrossRef
12.
Zurück zum Zitat Scottish Executive Health Department (2005a) Delivering for Health Edinburgh. Scottish Executive Health Department, Edinburgh Scottish Executive Health Department (2005a) Delivering for Health Edinburgh. Scottish Executive Health Department, Edinburgh
13.
Zurück zum Zitat McCaughan EM, Thompson KA (2000) Information needs of cancer patients receiving chemotherapy at a day-case unit in Northern Ireland. J Clin Nurs 9(6):851–858CrossRef McCaughan EM, Thompson KA (2000) Information needs of cancer patients receiving chemotherapy at a day-case unit in Northern Ireland. J Clin Nurs 9(6):851–858CrossRef
14.
Zurück zum Zitat Scottish Executive Health Department (2005b) National service framework for Service Change Edinburgh. Scottish Executive Health Department, Edinburgh Scottish Executive Health Department (2005b) National service framework for Service Change Edinburgh. Scottish Executive Health Department, Edinburgh
15.
Zurück zum Zitat Roine R, Ohinmaa A, Hailey D (2001) Assessing telemedicine: a systematic review of the literature. CMAJ 165(6):765–771PubMed Roine R, Ohinmaa A, Hailey D (2001) Assessing telemedicine: a systematic review of the literature. CMAJ 165(6):765–771PubMed
17.
Zurück zum Zitat Barnett TE, Chumbler NR, Vogel WB, Beyth RJ, Qin H, Kobb R (2006) The effectiveness of a care coordination home telehealth program for veterans with diabetes mellitus: a 2-year follow-up. Am J Manag Care 12(8):467–474PubMed Barnett TE, Chumbler NR, Vogel WB, Beyth RJ, Qin H, Kobb R (2006) The effectiveness of a care coordination home telehealth program for veterans with diabetes mellitus: a 2-year follow-up. Am J Manag Care 12(8):467–474PubMed
18.
Zurück zum Zitat Biermann E, Dietrich W, Rihl J, Standl E (2002) Are there time and cost savings by using telemanagement for patients on intensified insulin therapy? A randomised, controlled trial. Comput Methods Programs Biomed 69(2):137–146 doi:10.1016/S0169-2607(02)00037-8 PubMedCrossRef Biermann E, Dietrich W, Rihl J, Standl E (2002) Are there time and cost savings by using telemanagement for patients on intensified insulin therapy? A randomised, controlled trial. Comput Methods Programs Biomed 69(2):137–146 doi:10.​1016/​S0169-2607(02)00037-8 PubMedCrossRef
19.
Zurück zum Zitat Chumbler NR, Neugaard B, Kobb R, Ryan P, Qin H, Joo Y (2005) Evaluation of a care coordination/home-telehealth program for veterans with diabetes: health services utilization and health-related quality of life. Eval Health Prof 28(4):464–478 doi:10.1177/0163278705281079 PubMedCrossRef Chumbler NR, Neugaard B, Kobb R, Ryan P, Qin H, Joo Y (2005) Evaluation of a care coordination/home-telehealth program for veterans with diabetes: health services utilization and health-related quality of life. Eval Health Prof 28(4):464–478 doi:10.​1177/​0163278705281079​ PubMedCrossRef
22.
Zurück zum Zitat Maguire R, Miller M, Sage M, Norrie J, McCann L, Taylor L et al (2005) Results of a UK based pilot study of a mobile phone based advanced symptom management system (ASyMS) in the remote monitoring of chemotherapy related toxicity. Clin Eff Nurs 9(3–4):202–210 (Sept–Dec)CrossRef Maguire R, Miller M, Sage M, Norrie J, McCann L, Taylor L et al (2005) Results of a UK based pilot study of a mobile phone based advanced symptom management system (ASyMS) in the remote monitoring of chemotherapy related toxicity. Clin Eff Nurs 9(3–4):202–210 (Sept–Dec)CrossRef
25.
Zurück zum Zitat Brown V, Sitzia J, Richardson A, Hughes J, Hannon H, Oakley C (2001) The development of the Chemotherapy Symptom Assessment Scale (C-SAS): a scale for the routine clinical assessment of the symptom experiences of patients receiving cytotoxic chemotherapy. Int J Nurs Stud 38(5):497–510 doi:10.1016/S0020-7489(00)00106-1 PubMedCrossRef Brown V, Sitzia J, Richardson A, Hughes J, Hannon H, Oakley C (2001) The development of the Chemotherapy Symptom Assessment Scale (C-SAS): a scale for the routine clinical assessment of the symptom experiences of patients receiving cytotoxic chemotherapy. Int J Nurs Stud 38(5):497–510 doi:10.​1016/​S0020-7489(00)00106-1 PubMedCrossRef
26.
Zurück zum Zitat The National Cancer Institute (2003) The common toxicity adverse events criteria. National Cancer Institute, Bethesda The National Cancer Institute (2003) The common toxicity adverse events criteria. National Cancer Institute, Bethesda
27.
Zurück zum Zitat Kearney N, Kidd L, Miller M, Sage M, Khorrami J, McGee M et al (2006) Utilising handheld computers to monitor and support patients receiving chemotherapy: results of a UK-based feasibility study. Support Cancer Care 14(7):742–752 doi:10.1007/s00520-005-0002-9 CrossRef Kearney N, Kidd L, Miller M, Sage M, Khorrami J, McGee M et al (2006) Utilising handheld computers to monitor and support patients receiving chemotherapy: results of a UK-based feasibility study. Support Cancer Care 14(7):742–752 doi:10.​1007/​s00520-005-0002-9 CrossRef
28.
Zurück zum Zitat McCloone P (2004) Carstairs scores for Scottish postcode sectors from the 2001 Census. Public Health Research Unit, University of Glasgow, Glasgow McCloone P (2004) Carstairs scores for Scottish postcode sectors from the 2001 Census. Public Health Research Unit, University of Glasgow, Glasgow
29.
Zurück zum Zitat Vogelzang NJ, Breitbart W, Cella D, Curt GA, Groopman JE, Horning SA et al (1997) Patient, caregiver and oncologist perceptions of cancer-related fatigue: results of a tripart assessment study. Semin Hematol 3(2):4–12 Vogelzang NJ, Breitbart W, Cella D, Curt GA, Groopman JE, Horning SA et al (1997) Patient, caregiver and oncologist perceptions of cancer-related fatigue: results of a tripart assessment study. Semin Hematol 3(2):4–12
32.
Zurück zum Zitat Eilers J, Berger AM, Peterson MC (1988) Development, testing, and application of the oral assessment. Oncol Nurs Forum 15:325–330PubMed Eilers J, Berger AM, Peterson MC (1988) Development, testing, and application of the oral assessment. Oncol Nurs Forum 15:325–330PubMed
34.
Zurück zum Zitat Gibson F, Aldiss S, McCann L, Maguire R, Miller M, Kearney N (2007) Using a mobile phone based advanced symptom management system to monitor and manage chemotherapy related toxicity. Pediatric Blood and Cancer 49(4):408 (Abstract 0.035 oral). Proceedings of the 39th Annual Conference of the International Society of Paediatric Oncology (SIOP), Mumbai, India Gibson F, Aldiss S, McCann L, Maguire R, Miller M, Kearney N (2007) Using a mobile phone based advanced symptom management system to monitor and manage chemotherapy related toxicity. Pediatric Blood and Cancer 49(4):408 (Abstract 0.035 oral). Proceedings of the 39th Annual Conference of the International Society of Paediatric Oncology (SIOP), Mumbai, India
35.
Zurück zum Zitat Maguire R, McCann L, Miller M, Kearney N (2008) Nurses perceptions and experiences of using a mobile phone based Advanced Symptom Management System (ASyMS©) to monitor and manage chemotherapy related toxicity. Eur J Oncol Nurs 12(4):380–386PubMedCrossRef Maguire R, McCann L, Miller M, Kearney N (2008) Nurses perceptions and experiences of using a mobile phone based Advanced Symptom Management System (ASyMS©) to monitor and manage chemotherapy related toxicity. Eur J Oncol Nurs 12(4):380–386PubMedCrossRef
36.
Zurück zum Zitat McCann L, Maguire R, Miller M, Kearney N (2008) Patients perceptions and experiences of using a mobile phone bases Advanced Symptom Management System (ASyMS©) to monitor and manage chemotherapy related toxicity. Eur J Cancer Care (Engl) (in press) McCann L, Maguire R, Miller M, Kearney N (2008) Patients perceptions and experiences of using a mobile phone bases Advanced Symptom Management System (ASyMS©) to monitor and manage chemotherapy related toxicity. Eur J Cancer Care (Engl) (in press)
37.
Zurück zum Zitat McCall K, Keen JN, Farrer K, Maguire R, McCann L, Johnston B, McGill M, Sage M, Kearney N (2008) Health professionals and patients perceptions of the use of a remote monitoring system (ASyMS©) in the recording and management of symptoms in patients receiving palliative care at home. Int J Palliat Nurs (in press) McCall K, Keen JN, Farrer K, Maguire R, McCann L, Johnston B, McGill M, Sage M, Kearney N (2008) Health professionals and patients perceptions of the use of a remote monitoring system (ASyMS©) in the recording and management of symptoms in patients receiving palliative care at home. Int J Palliat Nurs (in press)
38.
Zurück zum Zitat Office for National Statistics (2006) Cancer statistics registrations: registrations of cancer diagnosed in 2004, England. Series MB1 no. 35. Office for National Statistics, London Office for National Statistics (2006) Cancer statistics registrations: registrations of cancer diagnosed in 2004, England. Series MB1 no. 35. Office for National Statistics, London
43.
Zurück zum Zitat Diggle PJ, Heagerty PJ, Liang KY, Zeger SL (2002) Analysis of longitudinal data, 2nd edn. Oxford University Press, Oxford Diggle PJ, Heagerty PJ, Liang KY, Zeger SL (2002) Analysis of longitudinal data, 2nd edn. Oxford University Press, Oxford
Metadaten
Titel
Evaluation of a mobile phone-based, advanced symptom management system (ASyMS©) in the management of chemotherapy-related toxicity
verfasst von
N. Kearney
L. McCann
J. Norrie
L. Taylor
P. Gray
M. McGee-Lennon
M. Sage
M. Miller
R. Maguire
Publikationsdatum
01.04.2009
Verlag
Springer-Verlag
Erschienen in
Supportive Care in Cancer / Ausgabe 4/2009
Print ISSN: 0941-4355
Elektronische ISSN: 1433-7339
DOI
https://doi.org/10.1007/s00520-008-0515-0

Weitere Artikel der Ausgabe 4/2009

Supportive Care in Cancer 4/2009 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.